2015

Gilead Sciences acquires Phenex Pharmaceuticals’ NASH development program

Wednesday, January 7, 2015

Gilead Sciences, a biopharmaceutical company headquartered in Foster City, Calif., and Phenex Pharmaceuticals, a privately held German biotechnology company, have signed a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.

[Read More]

Intellia Therapeutics, Novartis partner

Wednesday, January 7, 2015

Intellia Therapeutics, a Cambridge, Mass.-based developer of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, has announced a five-year R&D collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs).

[Read More]

Pfizer acquires Redvax

Tuesday, January 6, 2015

Pfizer has acquired a controlling interest in Redvax, a spinoff from Redbiotec, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

[Read More]

U.S. immunity against legal claims given to developers of Ebola treatments

Monday, January 5, 2015

Health and Human Services Secretary Sylvia M. Burwell has announced a declaration under the Public Readiness and Emergency Preparedness (PREP) Act to facilitate the development and availability of experimental Ebola vaccines. This declaration is intended to assist in the global community’s effort to help combat the current epidemic in West Africa and help prevent future outbreaks there.

[Read More]

UPS to acquire Polish healthcare logistics company Poltraf

Monday, January 5, 2015

UPS has agreed to terms with Poland-based investment fund ORTIE to acquire its pharmaceutical logistics company Poltraf. The acquisition will further strengthen UPS’ healthcare experience and network in Europe, enabling compliant logistics services to customers for streamlining their product supply to the fast-growing healthcare markets of Central and Eastern Europe.

[Read More]